Preventive and Predictive Genetics: Towards Personalised Medicine

[1]  M. Wiese,et al.  Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis , 2013, Expert opinion on drug metabolism & toxicology.

[2]  J. Guimarães,et al.  Hereditary ataxia and spastic paraplegia in Portugal: a population-based prevalence study. , 2013, JAMA neurology.

[3]  M. Tamm,et al.  DMF inhibits PDGF-BB induced airway smooth muscle cell proliferation through induction of heme-oxygenase-1 , 2010, Respiratory research.

[4]  A. Szczepankiewicz,et al.  [Association of A/T polymorphism of the CHRM2 gene with bronchodilator response to ipratropium bromide in asthmatic children]. , 2008, Pneumonologia i alergologia polska.

[5]  Herb Chen,et al.  Synergistic Effect of Pasireotide and Teriflunomide in Carcinoids in vitro , 2012, Neuroendocrinology.

[6]  T. Mizutani PM Frequencies of Major CYPs in Asians and Caucasians , 2003, Drug metabolism reviews.

[7]  G. Aliev,et al.  Genomics of schizophrenia and pharmacogenomics of antipsychotic drugs , 2013 .

[8]  R. Cacabelos Pharmacogenetic Basis for Therapeutic Optimization in Alzheimer’s Disease , 2012, Molecular Diagnosis & Therapy.

[9]  D. Blacker,et al.  Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database , 2007, Nature Genetics.

[10]  G. Baker,et al.  Amine oxidases and their inhibitors: what can they tell us about neuroprotection and the development of drugs for neuropsychiatric disorders? , 2007, Journal of psychiatry & neuroscience : JPN.

[11]  Ammar Al-Chalabi,et al.  Clinical genetics of amyotrophic lateral sclerosis: what do we really know? , 2011, Nature Reviews Neurology.

[12]  Colin N A Palmer,et al.  Tailored second-line therapy in asthmatic children with the Arg(16) genotype. , 2013, Clinical science.

[13]  Janel O. Johnson,et al.  Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study , 2012, The Lancet Neurology.

[14]  J. Losy,et al.  CCL5, CXCL10 and CXCL11 Chemokines in Patients with Active and Stable Relapsing-Remitting Multiple Sclerosis , 2010, Neuroimmunomodulation.

[15]  R. Cacabelos,et al.  Genomics and Pharmacogenomics of Schizophrenia , 2011, CNS neuroscience & therapeutics.

[16]  K. Misulis,et al.  DEMYELINATING diseases. , 1952, Lancet.

[17]  R. Cacabelos Pharmacogenomics of Alzheimer’s Disease , 2011 .

[18]  M. Tachikawa,et al.  Roles of organic anion/cation transporters at the blood–brain and blood–cerebrospinal fluid barriers involving uremic toxins , 2011, Clinical and Experimental Nephrology.

[19]  E. Urcelay,et al.  IFN-beta pharmacogenomics in multiple sclerosis. , 2010, Pharmacogenomics.

[20]  M. Nishimura,et al.  Polymorphisms in the muscarinic receptor 1 gene confer susceptibility to asthma in Japanese subjects. , 2006, American journal of respiratory and critical care medicine.

[21]  K. Barnes Ancestry, ancestry-informative markers, asthma, and the quest for personalized medicine. , 2010, The Journal of allergy and clinical immunology.

[22]  Y. Okamoto,et al.  Tumor-suppressive sphingosine-1-phosphate receptor-2 counteracting tumor-promoting sphingosine-1-phosphate receptor-1 and sphingosine kinase 1 - Jekyll Hidden behind Hyde. , 2011, American journal of cancer research.

[23]  R. Cacabelos Pharmacogenomic Biomarkers in Neuropsychiatry: The Path to Personalized Medicine in Mental Disorders , 2009, The Handbook of Neuropsychiatric Biomarkers, Endophenotypes and Genes.

[24]  R. Kim,et al.  Molecular basis of ethnic differences in drug disposition and response. , 2001, Annual review of pharmacology and toxicology.

[25]  X. Montalban,et al.  Role of tumour necrosis factor (TNF)‐α and TNFRSF1A R92Q mutation in the pathogenesis of TNF receptor‐associated periodic syndrome and multiple sclerosis , 2011, Clinical and experimental immunology.

[26]  V. Haufroid Genetic polymorphisms of ATP-binding cassette transporters ABCB1 and ABCC2 and their impact on drug disposition. , 2011, Current drug targets.

[27]  Yoo-Hun Suh,et al.  Amyloid Precursor Protein, Presenilins, and α-Synuclein: Molecular Pathogenesis and Pharmacological Applications in Alzheimer's Disease , 2002, Pharmacological Reviews.

[28]  A. Townsend,et al.  Multidrug Resistance Protein 1 (MRP1, ABCC1) Mediates Resistance to Mitoxantrone via Glutathione-Dependent Drug Efflux , 2006, Molecular Pharmacology.

[29]  D. Shriner Overview of Admixture Mapping , 2017, Current protocols in human genetics.

[30]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[31]  C. Winkler,et al.  Admixture mapping comes of age. , 2010, Annual review of genomics and human genetics.

[32]  R. Cacabelos The Metabolomic Paradigm of Pharmacogenomics in Complex Disorders , 2012 .

[33]  Keith F. Tipton,et al.  The therapeutic potential of monoamine oxidase inhibitors , 2006, Nature Reviews Neuroscience.

[34]  D. Meyers,et al.  Pharmacogenetics: implications of race and ethnicity on defining genetic profiles for personalized medicine. , 2014, The Journal of allergy and clinical immunology.

[35]  Z. Kovarik,et al.  Mechanism of stereoselective interaction between butyrylcholinesterase and ethopropazine enantiomers. , 2011, Biochimie.

[36]  O. Ross A Prognostic View on the Application of Individualized Genomics in Parkinson’s Disease , 2013, Current Genetic Medicine Reports.

[37]  J. Robert,et al.  Pharmacogenetics of human carboxylesterase 2, an enzyme involved in the activation of irinotecan into SN‐38 , 2004, Clinical pharmacology and therapeutics.

[38]  A. Crowe,et al.  Oral and inhaled corticosteroids: differences in P-glycoprotein (ABCB1) mediated efflux. , 2012, Toxicology and applied pharmacology.

[39]  J. Donfack,et al.  Sequence variation in the promoter region of the cholinergic receptor muscarinic 3 gene and asthma and atopy. , 2003, The Journal of allergy and clinical immunology.

[40]  P. Gergen,et al.  Reported asthma among Puerto Rican, Mexican-American, and Cuban children, 1982 through 1984. , 1993, American journal of public health.

[41]  R. Chakraborty,et al.  V75R576 IL-4 receptor alpha is associated with allergic asthma and enhanced IL-4 receptor function. , 2002, Journal of immunology.

[42]  A. Goris,et al.  Send Orders of Reprints at Reprints@benthamscience.org Progress in Multiple Sclerosis Genetics , 2022 .

[43]  Pamela A McCombe,et al.  Effects of gender in amyotrophic lateral sclerosis. , 2010, Gender medicine.

[44]  C. Polman,et al.  Pharmacogenomics of Interferon-ß Therapy in Multiple Sclerosis: Baseline IFN Signature Determines Pharmacological Differences between Patients , 2008, PloS one.

[45]  Lee, Jk,et al.  Lebrikizumab treatment in adults with asthma. , 2011 .

[46]  Anil K. Malhotra,et al.  Genomics and the future of pharmacotherapy in psychiatry , 2007, International review of psychiatry.

[47]  Matthew C. Kiernan,et al.  Clinical diagnosis and management of amyotrophic lateral sclerosis , 2011, Nature Reviews Neurology.

[48]  S. Ying,et al.  Intron-mediated RNA interference and microRNA biogenesis. , 2009, Methods in molecular biology.

[49]  N. Hanania,et al.  Periostin, a novel biomarker of TH2-driven asthma , 2014, Current opinion in pulmonary medicine.

[50]  R. Bhatnagar,et al.  RNA Interference: Biology, Mechanism, and Applications , 2003, Microbiology and Molecular Biology Reviews.

[51]  K. Rhodes,et al.  Fumarates Promote Cytoprotection of Central Nervous System Cells against Oxidative Stress via the Nuclear Factor (Erythroid-Derived 2)-Like 2 Pathway , 2012, Journal of Pharmacology and Experimental Therapeutics.

[52]  R. Cacabelos Pharmacogenomics and therapeutic strategies for dementia , 2009, Expert review of molecular diagnostics.

[53]  I. Pavord,et al.  Efficacy and safety of etanercept in moderate-to-severe asthma: a randomised, controlled trial , 2010, European Respiratory Journal.

[54]  D. Selkoe,et al.  Deciphering the genetic basis of Alzheimer's disease. , 2002, Annual review of genomics and human genetics.

[55]  S. Wenzel,et al.  Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies , 2007, The Lancet.

[56]  W. Waldhäusl,et al.  Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: involvement of impaired integrin activation and immunologic synapse formation. , 2005, Arthritis and rheumatism.

[57]  K. Biglan,et al.  Therapeutics in Huntington’s Disease , 2012, Current Treatment Options in Neurology.

[58]  S. Szabo,et al.  Development of Spontaneous Airway Changes Consistent with Human Asthma in Mice Lacking T-bet , 2002, Science.

[59]  W. Poewe,et al.  Management of Motor and Non-Motor Symptoms in Parkinson’s Disease , 2013, CNS Drugs.

[60]  Ryan M Spengler,et al.  Rational design of therapeutic siRNAs: minimizing off-targeting potential to improve the safety of RNAi therapy for Huntington's disease. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[61]  K. Német,et al.  Leflunomide and its metabolite A771726 are high affinity substrates of BCRP: implications for drug resistance , 2008, Annals of the rheumatic diseases.

[62]  R. Cacabelos Molecular pathology and pharmacogenomics in Alzheimer's disease: polygenic-related effects of multifactorial treatments on cognition, anxiety and depression. , 2007, Methods and findings in experimental and clinical pharmacology.

[63]  Florence Demenais,et al.  A large-scale, consortium-based genomewide association study of asthma. , 2010, The New England journal of medicine.

[64]  N. Farahi,et al.  Asthma: beyond corticosteroid treatment , 2013, Archives of medical science : AMS.

[65]  R. Cacabelos Pharmacogenomics and therapeutic prospects in dementia , 2008, European Archives of Psychiatry and Clinical Neuroscience.

[66]  T. Ishikawa,et al.  Pharmacogenomics of drug transporters: a new approach to functional analysis of the genetic polymorphisms of ABCB1 (P-glycoprotein/MDR1). , 2004, Biological & pharmaceutical bulletin.

[67]  P. Barnes,et al.  New drugs for asthma , 1996, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[68]  A. Wimo,et al.  The global prevalence of dementia: A systematic review and metaanalysis , 2013, Alzheimer's & Dementia.

[69]  Magnus Ingelman-Sundberg,et al.  Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. , 2007, Pharmacology & therapeutics.

[70]  I. Tellado,et al.  Future Trends in the Pharmacogenomics of Brain Disorders and Dementia: Influence of APOE and CYP2D6 Variants , 2010, Pharmaceuticals.

[71]  Yoshiro Saito,et al.  Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1. , 2004, Drug metabolism and pharmacokinetics.

[72]  J. Sattabongkot,et al.  Leflunomide or A77 1726 protect from acetaminophen-induced cell injury through inhibition of JNK-mediated mitochondrial permeability transition in immortalized human hepatocytes. , 2006, Toxicology and applied pharmacology.

[73]  R. Cacabelos Pharmacogenomics of Central Nervous System (CNS) Drugs , 2012 .

[74]  R. Cacabelos,et al.  Isolation, sequence and genotyping of the drug metabolizer CYP2D6 gene in the Colombian population. , 2000, Methods and findings in experimental and clinical pharmacology.

[75]  C. Brightling,et al.  A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma , 2012, European Respiratory Journal.

[76]  J. Stevens,et al.  Involvement of human CYP1A isoenzymes in the metabolism and drug interactions of riluzole in vitro. , 1997, The Journal of pharmacology and experimental therapeutics.

[77]  H. Pehamberger,et al.  Combination of dacarbazine and dimethylfumarate efficiently reduces melanoma lymph node metastasis. , 2010, The Journal of investigative dermatology.

[78]  A. Puschmann Monogenic Parkinson's disease and parkinsonism: clinical phenotypes and frequencies of known mutations. , 2013, Parkinsonism & related disorders.

[79]  Hung Li,et al.  Carrier Screening for Spinal Muscular Atrophy (SMA) in 107,611 Pregnant Women during the Period 2005–2009: A Prospective Population-Based Cohort Study , 2011, PloS one.

[80]  Andrew D. Johnson,et al.  Polymorphisms affecting gene regulation and mRNA processing: broad implications for pharmacogenetics. , 2005, Pharmacology & therapeutics.

[81]  F. Patti,et al.  The pharmacokinetics of glatiramer acetate for multiple sclerosis treatment , 2013, Expert opinion on drug metabolism & toxicology.

[82]  P. Jarman,et al.  Genetics of movement disorders and ataxia , 2002, Journal of neurology, neurosurgery, and psychiatry.

[83]  A. Need,et al.  Priorities and standards in pharmacogenetic research , 2005, Nature Genetics.

[84]  P. Couraud,et al.  ABC AND SLC TRANSPORTER EXPRESSION AND POT SUBSTRATE CHRACTERIZATION ACROSS THE HUMAN CMEC/ D3 BLOOD-BRAIN BARRIER CELL LINE , 2010 .

[85]  M. Armstrong,et al.  Evidence-based guideline: Pharmacologic treatment of chorea in Huntington disease , 2012, Neurology.

[86]  C. Vedeler,et al.  Fc receptors for immunoglobulin G—a role in the pathogenesis of Guillain–Barré syndrome and multiple sclerosis , 2001, Journal of Neuroimmunology.

[87]  K. Ohta,et al.  Mutation screening of the muscarinic m2 and m3 receptor genes in asthmatics, outgrow subjects, and normal controls. , 2002, Annales de genetique.

[88]  M. Kubo,et al.  Genetic predictors associated with improvement of asthma symptoms in response to inhaled corticosteroids. , 2014, The Journal of allergy and clinical immunology.

[89]  Wei Duan,et al.  Clinical pharmacogenetics and potential application in personalized medicine. , 2008, Current drug metabolism.

[90]  D. Postma,et al.  Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction , 2009, Nature Genetics.

[91]  M. Bromberg,et al.  Amyotrophic Lateral Sclerosis: Drug Therapy from the Bench to the Bedside , 2012, Seminars in Neurology.

[92]  R. Weinshilboum,et al.  Pharmacogenetics and pharmacogenomics: development, science, and translation. , 2006, Annual review of genomics and human genetics.

[93]  E. Cook,et al.  Determination and analysis of single nucleotide polymorphisms and haplotype structure of the human carboxylesterase 2 gene. , 2004, Pharmacogenetics.

[94]  Paweł P Liberski,et al.  Gerstmann-Sträussler-Scheinker disease. I. Human diseases. , 2004, Folia neuropathologica.

[95]  M. Takeda,et al.  Molecular genetics of Alzheimer's disease and aging. , 2005, Methods and findings in experimental and clinical pharmacology.

[96]  M. Nishimura,et al.  Tissue-specific mRNA expression profiles of human solute carrier transporter superfamilies. , 2008, Drug metabolism and pharmacokinetics.

[97]  S. Wenzel,et al.  Dupilumab in persistent asthma with elevated eosinophil levels. , 2013, The New England journal of medicine.

[98]  F. Van Bambeke,et al.  ABC multidrug transporters: target for modulation of drug pharmacokinetics and drug-drug interactions. , 2011, Current drug targets.

[99]  S. Cavallaro,et al.  Identification of Pharmacological Targets in Amyotrophic Lateral Sclerosis Through Genomic Analysis of Deregulated Genes and Pathways , 2012, Current genomics.

[100]  P. Whittaker,et al.  RNA interference: From gene silencing to gene-specific therapeutics , 2005, Pharmacology & Therapeutics.

[101]  Vincenzo Bonifati,et al.  The genetics of Parkinson's disease: Progress and therapeutic implications , 2013, Movement disorders : official journal of the Movement Disorder Society.

[102]  Kenny Q. Ye,et al.  An integrated map of genetic variation from 1,092 human genomes , 2012, Nature.

[103]  J. Márki-Zay,et al.  MDR-ABC transporters: biomarkers in rheumatoid arthritis. , 2013, Clinical and experimental rheumatology.

[104]  P. Casarosa,et al.  Molecular basis for the long duration of action and kinetic selectivity of tiotropium for the muscarinic M3 receptor. , 2013, Journal of medicinal chemistry.

[105]  Christos Proukakis,et al.  A novel α-synuclein missense mutation in Parkinson disease , 2013, Neurology.

[106]  R. Cacabelos Pharmacogenomics and therapeutic prospects in Alzheimer’s disease , 2005, Expert opinion on pharmacotherapy.

[107]  K. Wolff,et al.  Dimethylfumarate Inhibits TNF-Induced Nuclear Entry of NF-κB/p65 in Human Endothelial Cells1 , 2002, The Journal of Immunology.

[108]  J. Leszek,et al.  Genomics of Dementia: APOE- and CYP2D6-Related Pharmacogenetics , 2012, International journal of Alzheimer's disease.

[109]  Carmen Fraile,et al.  Pharmacogenetic aspects of therapy with cholinesterase inhibitors: the role of CYP2D6 in Alzheimer's disease pharmacogenetics. , 2007, Current Alzheimer research.